OFIX Forms 3, 4 and 5: Stock Options

Orthofix Medical Inc. Forms 3, 4 and 5: Stock Options

Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 6 rows in 2026. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.

2026-03-03: Reporting owner Calafiore Massimo; Form 4; Security Employee Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
2026-03-03: Reporting owner McPherron Aviva; Form 4; Security Employee Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
2026-03-03: Reporting owner Andrews Julie; Form 4; Security Employee Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
2026-03-03: Reporting owner Cedron Jorge Andres; Form 4; Security Employee Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).

All rows

OFIX insiders transactions against the stock price

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

Logarithmic scale. Both lines share the same starting value for the selected range.

Markers: each transaction type positioned at that session's split-adjusted close. Tooltips retain the reported transaction price when available.

Transaction date	Reporting owner	Form	Security	Transaction	Shares	Price	Price that day	Filing
2026-03-03	Calafiore Massimo Director, Officer (President & CEO)	4	Employee Stock Option (Right to Buy) Derivative · Direct	A Grant, award or other acquisition pursuant to Rule 16b-3(d)	+273,279 273,279 owned after	$13.03 exercise price	$13.03	2026-03-05
2026-03-03	McPherron Aviva Officer (Pres, Global Ops & Qual)	4	Employee Stock Option (Right to Buy) Derivative · Direct	A Grant, award or other acquisition pursuant to Rule 16b-3(d)	+54,656 54,656 owned after	$13.03 exercise price	$13.03	2026-03-05
2026-03-03	Andrews Julie Officer (CFO)	4	Employee Stock Option (Right to Buy) Derivative · Direct	A Grant, award or other acquisition pursuant to Rule 16b-3(d)	+84,261 84,261 owned after	$13.03 exercise price	$13.03	2026-03-05
2026-03-03	Cedron Jorge Andres Officer (CLO)	4	Employee Stock Option (Right to Buy) Derivative · Direct	A Grant, award or other acquisition pursuant to Rule 16b-3(d)	+54,656 54,656 owned after	$13.03 exercise price	$13.03	2026-03-05
2026-03-03	Vitale Lucas Officer (CP&BOO)	4	Employee Stock Option (Right to Buy) Derivative · Direct	A Grant, award or other acquisition pursuant to Rule 16b-3(d)	+45,546 45,546 owned after	$13.03 exercise price	$13.03	2026-03-05
2026-03-03	Fisher Patrick Officer (President, Global Limb Recon)	4	Employee Stock Option (Right to Buy) Derivative · Direct	A Grant, award or other acquisition pursuant to Rule 16b-3(d)	+50,101 50,101 owned after	$13.03 exercise price	$13.03	2026-03-05

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Orchestra BioMed Holdings, Inc. (OBIO)	United States	$0.356B	-4.39
SHOULDER INNOVATIONS, INC. (SI)	United States	$0.355B
CARLSMED, INC. (CARL)	United States	$0.405B
Embecta Corp. (EMBC)	United States	$0.319B	2.10
ClearPoint Neuro, Inc. (CLPT)	United States	$0.446B	-15.74
TREACE MEDICAL CONCEPTS, INC. (TMCI)	United States	$0.297B	-4.32
Mobia Medical, Inc. (MOBI)	United States	$0.293B
TriSalus Life Sciences, Inc. (TLSI)	United States	$0.283B	-9.92
Cytosorbents Corp (CTSO)	United States	$0.274B	-1.29
ORASURE TECHNOLOGIES INC (OSUR)	United States	$0.272B	-6.26